Blood 2019; 133 (9): 886–888. Multivariate analysis revealed the following factors associated with higher CNS relapse risk: ABC subtype: HR = 5.2; (95% CI, 2.1−12.9); Unclassified COO subtype: HR = 4.2; (95% CI, 1.5−11.7); High CNS-IPI: HR = 4.0; (95% CI, 1.3−12.3); CNS-IPI and COO were combined to create a modified risk stratification model (CNS-IPI-C): According to this model, three CNS-IPI-C subgroups were identified as having low (48.2%), intermediate (one risk factor; 43.7%) and high (two risk factors; 8.0%) CNS relapse risk, Low CNS-IPI-C risk: 0.5% (95% CI, 0.0−1.3), Intermediate CNS-IPI-C risk: 4.4% (95% CI, 2.2−6.6), High CNS-IPI-C risk: 15.2% (95% CI, 5.4−24.0), This modified model resulted in a 22-fold higher risk of CNS relapse in the high, There was no difference in CNS relapse in newly-diagnosed DLBCL patients treated with either G-CHOP or R-CHOP, High CNS-IPI score and ABC or unclassified COO subtypes were independent risk factors for CNS relapse in DLBCL, Combining CNS-IPI score and COO improved identification of DLBCL patients with different CNS relapse risks, No significant difference in the incidence of CNS relapse was observed between the intermediate and low risk CNS-IPI subgroups. Notwithstanding improvements in treatment of established CNS relapse in DLBCL,2 such events are devastating for patients and frequently associated with neurocognitive disability and short survival times. Mice: 15 mg/kg[2] (p.o. The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. However, this issue remains controversial with clinical and pathological case selection bias likely to be confounding factors. 2019 Feb 1;442:91-103. I have been having trouble updating my profie, but will update it once I figure things out. Hackensack University Medical Center These limitations speak to the need for reliable biomarkers to more clearly delineate risk groups. Boston, Massachusetts, United States, 02215 The study was registered at www.clinicaltrials.gov as #NCT01287741. On 7 January 2019, Lymphoma Hub, All content on this site is intended for healthcare professionals only. Interestingly, CDKN2A loss and MYD88 mutation were the most commonly observed alterations in patients with CNS relapse in the GOYA study. Boston, Massachusetts, United States, 02215 Unfortunately, my latest scan indicates it did not work and my doctor wants to put me on Sutent. This suprised me because I was hoping my cancer was caught early' however, cancer had other plans for me. Melanoma (Part E) Sorry, need to update my profile. San Antonio, Texas, United States, 78229, Neurodegenerative Diseases Compound Library, Human Endogenous Metabolite Compound Library, Small Molecule Immuno-Oncology Compound Library, Differentiation Inducing Compound Library, Targeting Tumor Metabolism Compound Library. Full details on my Profile Page. For example, patients with a high CNS IPI (score, 4-6) have a predicted 2-year CNS relapse rate of 10.2% 10 ; 151 patients in our study fell into this category but had a 2-year CNS relapse risk of 6.4%. In the GOYA phase III trial, these patients were 1:1 randomized according to planned number of CHOP cycles, IPI, and geographic region to either: G-CHOP: 1000 mg of G on Day 1,8, and 15 of cycle 1 and on Day 1 of cycles 2−8. New York, New York, United States, 10065 lymphoma & CLL [2] Kaneda MM, Messer KS, et al. doi: https://doi.org/10.1182/blood-2019-01-897595. My hubby has been getting infusions of it for the past 6 1/2 months with no side effects (so far anyway). Recruiting I had slow, but steady progression. Thanx for your kind works. Hematology Oncology Associates of the Treasure Coast South Texas Accelerated Research and Treatment (START) Santa Monica, California, United States, 90404 This is an important paper contributing to a difficult clinical issue. [19] Table 2 also describes additional clinical factors associated with increased risk of CNS … Non-small Cell Lung Cancer (Part E) Christopher P. Fox; Refining CNS relapse risk in DLBCL: easy as ABC?. received research funding from AbbVie, Adienne, Gilead, and Roche; received advisory board honoraria from AbbVie, Adienne, Atarabio, Celgene, Gilead, Janssen, Roche, Sunesis, and Takeda; and received travel support from AbbVie, Celgene, Gilead, Janssen, Roche, and Takeda.